Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning

16. november 2026 opdateret af: HALEON

A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning

The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

2100

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Marina Centre
      • Singapore, Marina Centre, Singapore
        • Virtual site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Beskrivelse

Inclusion Criteria:

  • Residents of Australia, Malaysia, Colombia, Kenya.
  • Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
  • Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
  • Self-reported healthy individuals.
  • Able to provide informed consent.
  • The specific Panadol/Dolex variant for each country as applicable.

Exclusion Criteria:

  • Participants who experience headaches that occur 15 or more days per month.
  • Participants with migraine.
  • Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
  • Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
  • Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
  • Participants affiliated with Sponsor or Contract Research Organization (CRO).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Panadol/Dolex Tablet

Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Paracetamol 500 milligram (mg) taken orally.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pain Intensity Before Using Panadol/Dolex
Tidsramme: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome.

Within the past 1 month from time of participation
Perceived Relief From Panadol/Dolex Use
Tidsramme: Within the past 1 month from time of participation

Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex.

Within the past 1 month from time of participation
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Tidsramme: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life.

Within the past 1 month from time of participation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Frequency of Panadol/Dolex Use
Tidsramme: Within the past 1 month from time of participation

Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day.

Within the past 1 month from time of participation
Timepoint of Panadol/Dolex Use
Tidsramme: Within the past 1 month from time of participation

Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options.

Within the past 1 month from time of participation
Product Satisfaction
Tidsramme: Within the past 1 month from time of participation

Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied.

Within the past 1 month from time of participation
Headache Management Behaviors
Tidsramme: Within the past 1 month from time of participation

Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Trust in The Product
Tidsramme: Within the past 1 month from time of participation

Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Value For Money
Tidsramme: Within the past 1 month from time of participation

Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Tidsramme: Within the past 1 month from time of participation

Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Tidsramme: Within the past 1 month from time of participation

Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options.

Within the past 1 month from time of participation

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

16. oktober 2026

Først indsendt, der opfyldte QC-kriterier

26. oktober 2026

Først opslået (Faktiske)

2. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

IPD-delingstidsramme

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD-delingsadgangskriterier

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner